CYP3A4-Mediated oxygenation versus dehydrogenation of raloxifene.
Raloxifene was approved in 2007 by the FDA for the chemoprevention of breast cancer in postmenopausal women at high risk for invasive breast cancer. Approval was based in part on the improved safety profile for raloxifene relative to the standard treatment of tamoxifen. However, recent studies have demonstrated the ability of raloxifene to form reactive intermediates and act as a mechanism-based inhibitor of cytochrome P450 3A4 (CYP3A4) by forming adducts with the apoprotein. However, previous studies could not differentiate between dehydrogenation to a diquinone methide and the more common oxygenation pathway to an arene oxide as the most likely intermediate to inactivate CYP3A4. In the current work, (18)O-incorporation studies were utilized to carefully elucidate CYP3A4-mediated oxygenation versus dehydrogenation of raloxifene. These studies established that 3'-hydroxyraloxifene is produced exclusively via CYP3A4-mediated oxygenation and provide convincing evidence for the mechanism of CYP3A4-mediated dehydrogenation of raloxifene to a reactive diquinone methide, while excluding the alternative arene oxide pathway. Furthermore, it was demonstrated that 7-hydroxyraloxifene, which was previously believed to be a typical O(2)-derived metabolite of CYP3A4, is in fact produced by a highly unusual hydrolysis pathway from a putative ester, formed by the conjugation of raloxifene diquinone methide with a carboxylic acid moiety of CYP3A4, or other proteins in the reconstituted system. These findings not only confirm CYP3A4-mediated dehydrogenation of raloxifene to a reactive diquinone methide but also suggest a novel route of raloxifene toxicity.
Moore
Chad D
CD
Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA.
Reilly
Christopher A
CA
Yost
Garold S
GS
D001059:Apoproteins / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000517:prevention & control; D018890:Chemoprevention; D051544:Cytochrome P-450 CYP3A / Q000378:metabolism*; D004249:DNA Damage; D005260:Female; D006801:Humans; D020849:Raloxifene Hydrochloride / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D013629:Tamoxifen / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*
D001059:Apoproteins; D013629:Tamoxifen; D020849:Raloxifene Hydrochloride; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human
Drug Metab Dispos. 2002 Jun;30(6):694-700
12019197
Carcinogenesis. 1994 Oct;15(10):2087-94
7955037
J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88
9747868
J Clin Oncol. 1993 Mar;11(3):485-90
8383191
Arch Biochem Biophys. 1998 Feb 15;350(2):223-32
9473295
Carcinogenesis. 1997 Oct;18(10):1949-54
9364005
J Med Chem. 1984 Aug;27(8):1057-66
6431104
Drugs. 2000 Aug;60(2):379-411
10983739
Chem Res Toxicol. 2007 Oct;20(10):1373-8
17867646
J Phys Chem B. 2009 Oct 1;113(39):13018-25
19728720
Cancer Res. 1992 Mar 1;52(5):1360-3
1737398
J Natl Cancer Inst. 1994 Apr 6;86(7):527-37
8133536
J Clin Oncol. 2008 Sep 1;26(25):4151-9
18757329
Recent Results Cancer Res. 2009;181:113-9
19213563
Chem Res Toxicol. 2005 Feb;18(2):162-73
15720120
N Engl J Med. 1998 Nov 26;339(22):1609-18
9828250
J Natl Cancer Inst. 1996 Jun 19;88(12):832-4
8637050
Drug Metab Rev. 2004 May;36(2):199-218
15237851
Chem Res Toxicol. 2002 Jul;15(7):907-14
12119000
N Engl J Med. 1998 Oct 1;339(14):974-84
9753714
Chem Res Toxicol. 2005 Sep;18(9):1485-96
16167842
Chem Res Toxicol. 2007 Nov;20(11):1676-84
17630709
Carcinogenesis. 1999 Mar;20(3):471-7
10190564
Chem Res Toxicol. 1989 Sep-Oct;2(5):280-1
2519818
Biomed Environ Mass Spectrom. 1990 Apr;19(4):211-7
2340358
Chem Res Toxicol. 2007 Jun;20(6):954-64
17497897
Chem Res Toxicol. 2007 Dec;20(12):1778-86
18001057
J Natl Cancer Inst. 2005 Mar 2;97(5):375-84
15741574
Chem Res Toxicol. 2004 Jul;17(7):879-88
15257612
J Biol Chem. 1989 May 5;264(13):7584-9
2708380
Chem Res Toxicol. 2008 Sep;21(9):1814-22
18690722
Expert Rev Anticancer Ther. 2009 Jan;9(1):51-60
19105706
Methods Enzymol. 2004;378:110-23
15038960